China Pharma (CPHI) 10-Q 13 Aug 21 2021 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 05, 2021
Document Information Line Items
Entity Registrant Name	CHINA PHARMA HOLDINGS, INC.
Trading Symbol	CPHI
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		43,579,557
Amendment Flag	false
Entity Central Index Key	0001106644
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-34471
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	75-1564807
Entity Address, Address Line One	Second Floor, No. 17
Entity Address, Address Line Two	Jinpan Road Haikou
Entity Address, City or Town	Hainan Province
Entity Address, Country	CN
Entity Address, Postal Zip Code	570216
City Area Code	86
Local Phone Number	898-6681-1730
Title of 12(b) Security	Common Stock
Security Exchange Name	NYSE
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 1,754,868	$ 957,653
Banker’s acceptances		53,736
Trade accounts receivable, less allowance for doubtful accounts of $18,316,990 and $18,150,493, respectively	409,675	501,892
Other receivables, less allowance for doubtful accounts of $30,142 and $22,320, respectively	63,770	27,652
Advances to suppliers	2,963	2,238
Inventory	2,978,060	3,705,119
Prepaid expenses	54,034	73,668
Total Current Assets	5,263,370	5,321,958
Property, plant and equipment, net	14,346,122	15,564,200
Operating lease right of use asset	169,807	49,687
Intangible assets, net	164,942	182,146
TOTAL ASSETS	19,944,241	21,117,991
Current Liabilities:
Trade accounts payable	687,052	1,234,594
Accrued expenses	332,393	177,359
Other payables	3,051,694	2,748,208
Advances from customers	525,579	719,786
Borrowings from related parties	2,824,019	2,134,428
Operating lease liability	83,707	52,070
Construction loan facility	2,167,149	2,298,886
Current portion of lines of credit	2,523,181	2,038,345
Total Current Liabilities	12,194,774	11,403,676
Non-current Liabilities:
Lines of credit, net of current portion	325,072	904,228
Operating lease liability, net of current portion	86,186
Deferred tax liability	813,636	805,556
Total Liabilities	13,419,668	13,113,460
Commitments and Contingencies (Note 9)
Stockholders’ Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding
Common stock, $0.001 par value; 95,000,000 shares authorized; 45,579,557 shares and 45,579,557 shares issued and outstanding, respectively	45,580	45,580
Additional paid-in capital	24,452,684	24,452,684
Retained deficit	(30,431,267)	(28,839,179)
Accumulated other comprehensive income	12,457,576	12,345,446
Total Stockholders' Equity	6,524,573	8,004,531
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 19,944,241	$ 21,117,991

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Trade accounts receivable, less allowance for doubtful accounts (in Dollars)	$ 18,316,990	$ 18,150,493
Other receivables, less allowance for doubtful accounts (in Dollars)	$ 30,142	$ 22,320
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	45,579,557	45,579,557
Common stock, shares outstanding	45,579,557	45,579,557

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenue	$ 2,415,559	$ 3,770,723	$ 4,773,930	$ 5,534,678
Cost of revenue	2,344,559	2,620,925	4,430,200	4,190,441
Gross profit	71,000	1,149,798	343,730	1,344,237
Operating expenses:
Selling expenses	445,478	727,642	823,813	1,053,737
General and administrative expenses	329,758	322,445	738,756	711,004
Research and development expenses	53,456	30,044	243,542	78,863
Bad debt (benefit) expense	(4,744)	(5,318)	(12,965)	24,928
Total operating expenses	823,948	1,074,813	1,793,146	1,868,532
(Loss) income from operations	(752,948)	74,985	(1,449,416)	(524,295)
Other income (expense):
Interest income	579	1,212	985	1,598
Interest expense	(72,392)	(63,144)	(143,657)	(125,147)
Net other expense	(71,813)	(61,932)	(142,672)	(123,549)
(Loss) income before income taxes	(824,761)	13,053	(1,592,088)	(647,844)
Income tax expense
Net (loss) income	(824,761)	13,053	(1,592,088)	(647,844)
Other comprehensive income (loss) - foreign currency translation adjustment	183,455	5,796	112,130	(191,236)
Comprehensive (loss) income	$ (641,306)	$ 18,849	$ (1,479,958)	$ (839,080)
(Loss) Earnings per share:
Basic and diluted (in Dollars per share)	$ (0.02)	$ 0	$ (0.03)	$ (0.01)
Weighted average shares outstanding (in Shares)	45,579,557	43,579,557	45,579,557	43,579,557

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders’ Equity - USD ($)	Common Stock	Additional Paid-in Capital	Retained Deficit	Accumulated Other Comprehensive Income	Total
Balance at Dec. 31, 2019	$ 43,580	$ 23,590,204	$ (25,972,402)	$ 11,576,219	$ 9,237,601
Balance (in Shares) at Dec. 31, 2019	43,579,557
Net income (loss)			(660,897)		(660,897)
Foreign currency translation adjustment				(197,032)	(197,032)
Balance at Mar. 31, 2020	$ 43,580	23,590,204	(26,633,299)	11,379,187	8,379,672
Balance (in Shares) at Mar. 31, 2020	43,579,557
Net income (loss)			13,053		13,053
Foreign currency translation adjustment				5,796	5,796
Balance at Jun. 30, 2020	$ 43,580	23,590,204	(26,620,246)	11,384,983	8,398,521
Balance (in Shares) at Jun. 30, 2020	43,579,557
Balance at Dec. 31, 2020	$ 45,580	24,452,684	(28,839,179)	12,345,446	8,004,531
Balance (in Shares) at Dec. 31, 2020	45,579,557
Net income (loss)			(767,327)		(767,327)
Foreign currency translation adjustment				(71,325)	(71,325)
Balance at Mar. 31, 2021	$ 45,580	24,452,684	(29,606,506)	12,274,121	7,165,879
Balance (in Shares) at Mar. 31, 2021	45,579,557
Net income (loss)			(824,761)		(824,761)
Foreign currency translation adjustment				183,455	183,455
Balance at Jun. 30, 2021	$ 45,580	$ 24,452,684	$ (30,431,267)	$ 12,457,576	$ 6,524,573
Balance (in Shares) at Jun. 30, 2021	45,579,557

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows from Operating Activities:
Net loss	$ (1,592,088)	$ (647,844)
Depreciation and amortization	1,400,647	1,305,070
Bad debt (benefit) expense	(12,965)	24,928
Inventory write off	121,604
Changes in assets and liabilities:
Trade accounts and other receivables	(120,757)	(305,183)
Advances to suppliers	(702)	(279,380)
Inventory	890,435	(14,136)
Trade accounts payable	(558,912)	(323,470)
Other payables and accrued expenses	447,500	199,781
Change in bankers’ acceptance notes payable		115,468
Advances from customers	(201,063)	95,579
Prepaid expenses	25,421	(323,553)
Net Cash Provided by (Used in) Operating Activities	399,120	(152,740)
Cash Flows from Investing Activities:
Purchases of property and equipment	(15,022)	(840,449)
Net Cash Used in Investing Activities	(15,022)	(840,449)
Cash Flows from Financing Activities:
Payments of construction term loan	(154,516)	(142,209)
Payments of line of credit	(896,194)
Borrowings and interest from related party	932,876	90,551
Repayments to related party	(251,861)
Proceeds from lines of credit	772,581	1,919,818
Net Cash provided by Financing Activities	402,886	1,868,160
Effect of Exchange Rate Changes on Cash	10,231	(23,318)
Net Increase in Cash, Cash Equivalents and Restricted Cash	797,215	851,653
Cash and Cash Equivalents at Beginning of Period	957,653	1,184,887
Cash, Cash Equivalents and Restricted Cash at End of Period	1,754,868	2,036,540
Cash and Cash Equivalents	1,754,868	1,813,544
Restricted cash		222,996
Cash, Cash Equivalents and Restricted Cash at End of Period	1,754,868	2,036,540
Supplemental Cash Flow Information:
Cash paid for income taxes
Cash paid for interest	121,090	118,374
Supplemental Noncash Investing and Financing Activities:
Accounts receivable collected with banker’s acceptances	195,021	270,453
Inventory purchased with banker’s acceptances	249,198	$ 304,520
Right-of-use assets obtained in exchange for operating lease obligations	$ 168,077

Organization and Significant Ac

Organization and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy. Liquidity and Going Concern As of June 30, 2021, the Company had cash and cash equivalents of $1.8 million and an accumulated deficit of $30.4 million. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $1,469,452 at June 30, 2021 to provide working capital and enable the Company to make the required payments related to its construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above. Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (the “SEC”) on March 26, 2021 (“2020 Annual Report”). Accounting Estimates The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. Reclassification Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326) In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
INVENTORY	NOTE 2 – INVENTORY Inventory consisted of the following: June 30, December 31, 2021 2020 Raw materials $ 1,755,110 $ 2,081,745 Work in process 461,293 662,999 Finished goods 761,657 960,375 Total Inventory $ 2,978,060 $ 3,705,119

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	NOTE 3 – PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment consisted of the following: June 30, December 31, 2021 2020 Permit of land use $ 436,011 $ 431,681 Building 10,124,855 10,024,303 Plant, machinery and equipment 29,306,831 29,018,708 Motor vehicle 332,967 329,660 Office equipment 274,687 259,175 Total 40,475,351 40,063,527 Less: accumulated depreciation (26,129,229 ) (24,499,327 ) Property, plant and equipment, net $ 14,346,122 $ 15,564,200 Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows: Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5 Depreciation relating to office equipment was included in general and administrative expenses, while all other depreciation was included in cost of revenue. Depreciation expense was $690,943 and $640,473 for the three months ended June 30, 2021 and 2020, respectively and $1,381,650 and $1,287,586 for the six months ended June 30, 2021 and 2020, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 4 - INTANGIBLE ASSETS Intangible assets represent the cost of medical formulas approved for production by the NMPA. The Company did not obtain NMPA production approval for any new medical formulas during the six months ended June 30, 2021 and 2020 and no costs were reclassified from advances to intangible assets during the six months ended June 30, 2021 and 2020, respectively. Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. Amortization expense relating to intangible assets was $9,517 and $8,676 for the three months ended June 30, 2021 and 2020, respectively and $18,997 and $17,484 for the six months ended June 30, 2021 and 2020, respectively which was included in the general and administrative expenses. Medical formulas typically do not have a residual value at the end of their amortization period. The Company evaluates each approved medical formula for impairment at the date of NMPA approval, when indications of impairment are present and also at the date of each financial statement. The Company’s evaluation is based on an estimated undiscounted net cash flow model, which considers currently available market data for the related drug and the Company’s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the fair value of the medical formula, which is determined by the estimated discounted future net cash flows. No impairment loss was recognized during the six months ended June 30, 2021 and 2020. Intangible assets consisted solely of NMPA approved medical formulas as follows: June 30, December 31, 2021 2020 Gross carrying amount $ 5,225,716 $ 5,173,818 Accumulated amortization (5,060,774 ) (4,991,672 ) Net carrying amount $ 164,942 $ 182,146

Other Payables

Other Payables	6 Months Ended
	Jun. 30, 2021
Other Payables [Abstract]
OTHER PAYABLES	NOTE 5 – OTHER PAYABLES Other Payables consisted of the following: June 30, December 31, 2021 2020 Compensation payable to officer $ 1,820,528 $ 1,815,990 Compensation and interest to related party 397,259 382,486 Other payables expenses $ 833,907 $ 549,732 Total Other Payables $ 3,051,694 $ 2,748,208

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 6 – RELATED PARTY TRANSACTIONS A member of the Company’s board of directors (“Board”) had previously advanced to the Company an aggregate amount of $1,354,567 as of June 30, 2021 and December 31, 2020 which are recorded as “Borrowings from related parties” on the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of 1.0% per year. Total interest expense for each of the three months ended June 30, 2021 and 2020 was $3,386 and $3,386, respectively and $6,773 and $6,773 for the six months ended June 30, 2021, respectively. Compensation and interest payable to the board member is included in Other payables in the accompanying condensed consolidated balance sheet totaling $397,259 and $382,486 as of June 30, 2021 and December 31, 2020, respectively. The Company received advances totaling $917,827 and repaid $251,861 of the advances during the six months ended June 30, 2021 from its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. Total amounts owed were $1,469,452 and $779,861 and are recorded as Borrowings from related parties on the accompanying condensed consolidated balance sheets as of June 30, 2021 and December 31, 2020, respectively. On July 8, 2019 the Company entered into a loan agreement in exchange for cash of RMB 4,770,000 ($738,379) with its Chairperson, Chief Executive Officer and Interim Chief Financial Officer. The loan bears interest at a rate of 4.35% and is payable within one year of the loan agreement. The due date of the loan agreement was extended to July 10, 2021 and further extended to July 9, 2022 on identical terms. Total interest expense related to the loan for the three months ended June 30, 2021 and 2020 was $7,539 and $7,433, respectively and $15,050 and $14,754 for the six months ended June 30, 2021 and 2020, respectively. Compensation payable to the Chairperson, Chief Executive Officer and Interim Chief Financial Officer is included in Other payables in the accompanying condensed consolidated balance sheet totaling $1,820,528 and $1,815,990 as of June 30, 2021 and December 31, 2020, respectively.

Banker's Acceptance Notes Payab

Banker's Acceptance Notes Payable	6 Months Ended
	Jun. 30, 2021
Banker's Acceptance Notes Payable [Abstract]
BANKER'S ACCEPTANCE NOTES PAYABLE	NOTE 7 – BANKER’S ACCEPTANCE NOTES PAYABLE In April 2016, the Company entered into a Banker’s Acceptance Note Agreement with a bank. Pursuant to the terms of the agreement, the Company can issue banker’s acceptance notes to any third party as payment of amounts owing to that third party. The Company is required to deposit with the bank an amount equal to the amounts represented by the banker’s acceptance notes issued to the third parties. The maximum amount that the Company can issue under this agreement is limited to the lesser of RMB30,000,000 (approximately $4.5 million) or the amount of cash available to deposit against the banker’s acceptance notes. In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank. As of June 30, 2021 and December 31, 2020, the Company had no outstanding banker’s acceptance notes payable.

Construction Loan Facility and

Construction Loan Facility and Lines of Credit	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
CONSTRUCTION LOAN FACILITY AND LINES OF CREDIT	NOTE 8 – CONSTRUCTION LOAN FACILITY AND LINES OF CREDIT The Company obtained a construction loan facility, dated June 21, 2013, in the aggregate amount of RMB 80,000,000 (approximately $13 million). The loan facility is for an eight-year term, which commenced on July 11, 2013, the initial draw-down date. The proceeds of the loan were used for and are collateralized by the construction of the Company’s new production facility and the included production line equipment and machinery. The loan bears interest based upon 110% of the PRC government’s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. The interest rate has remained at 5.39% on each of the July 10 anniversary dates since inception. The loan required interest only payments for the first two years. Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2021 on the identical terms as described above for 2015. The Company has made all required payments due under the loan. As of June 30, 2021, the Company had no additional amounts available to it under this facility. During the six months ended June 30, 2021, the Company made principal payments in the amount of $154,516 (RMB 1,000,000). The Company made the required RMB 14,000,000 (approximately $2.2 million) payment due under the loan on July 10, 2021. Lines of Credit In April 2020, the Company obtained a line of credit from Postal Savings Bank of China for an aggregate amount of RMB 10,000,000 (approximately $1.4 million), of which RMB 5,000,000 (approximately $0.7 million) were advanced in April 2020, and RMB 3,000,000 (approximately $0.4 million) were advanced in July 2020. The loan bears interest at a rate of 4.25% per annum. Advances on the line of credit are due two years from the date of the advance. A third party company has guaranteed the loan as being a second priority creditor in the collateral in certain land use rights and buildings next to the creditor of the construction loan facility as discussed above. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit. The Company has an additional RMB 2,000,000 (approximately $0.3 million) available under the line, subject to a risk review and approval by the third party guarantee company. Total interest expense under this facility for the three months ended June 30, 2021 and 2020 was $11,550 and $4,963, respectively. Total interest expense under this facility for the six months ended June 30, 2021 and 2020 was $23,517 and $4,963, respectively. The Company repaid RMB 800,000 (approximately $0.12 million) during the six months ended June 30, 2021 as per the repayment schedule. On June 30, 2020 the Company obtained a line of credit with Bank of Communications for an aggregate amount of RMB 8,500,000 (approximately $1.2 million), all of which have been advanced. The loan bears interest at the rate of 4.05% per annum. The line of credit is due in one year on the anniversary date of the line of credit. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. On June 21, 2021 the Company paid the balance in full. On June 25, 2021 the Company entered into a new loan bearing an interest rate of 4.17%. The line of credit is due in one year on the anniversary date of the line of credit. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest expense for the three months ended June 30, 2021 and 2020 was $11,550 and $0, respectively. Total interest expense for the six months ended June 30, 2021 and 2020 was $23,517 and $0, respectively. The Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October 2020 under this line. The loan bears interest at the rate of 4.50% per annum. The line of credit is due in one year on the anniversary date of the advance. In addition, the Company’s Chief Executive Officer and Chair of the Board personally guaranteed the new line of credit and pledged personal assets as collateral for the loan. Total interest for the three months ended June, 2021 and 2020 was $5,697 and $0, respectively. Total interest for the six months ended June, 2021 and 2020 was $11,249 and $0, respectively. Principal payments required for the remaining terms of the loan facility and lines of credit as of June 30, 2021 are as follows: Year Lines of Construction Total 2021 $ 2,523,181 $ 2,167,149 $ 4,690,330 2022 325,072 - 325,072 $ 2,848,253 $ 2,167,149 $ 5,015,402 Fair Value of Construction Loan Facility

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
LEASES	NOTE 9 - LEASES The Company has leases for certain office and production facilities in the PRC which are classified as operating leases. The leases contain payment terms for fixed amounts. Options to extend are recognized as part of the lease liabilities and recognized as right to use assets when management estimates to renew the lease. There are no residual value guarantees, no variable lease payments, and no restrictions or covenants imposed by leases. The discount rate used in measuring the lease liabilities and right of use assets was determined by reviewing the Company’s incremental borrowing rate at the initial measurement date. For the three months ended June 30, 2021 and 2020, operating lease cost was $24,793 and $22,265, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $26,352 and $23,665, respectively. For the six months ended June 30, 2021 and 2020, operating lease cost was $48,760 and $44,494, respectively and cash paid for amounts included in the measurement of lease liabilities for operating cash flows from operating leases was $51,827 and $49,376, respectively. As of June 30, 2021 and December 31, 2020, the Company reported operating lease right of use assets of $169,807 and $49,687, respectively and operating use liabilities of $169,893 and $52,070, respectively. As of June 30, 2021, its operating leases had a weighted average remaining lease term of 1.98 years and a weighted average discount rate of 4.75%. Minimum lease payments for the Company’s operating lease liabilities were as follows for the twelve month periods ended June 30: 2022 $ 89,937 2023 88,420 Total undiscounted cash flows 178,357 Less: Imputed interest (8,464 ) 169,893 Less: Operating lease liabilities, current portion (83,707 ) Operating lease liabilities, net of current portion $ 86,186 The Company has leases with terms less than one year for certain provincial sales offices that are not material.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10 - INCOME TAXES Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect of a change in tax laws or rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. Liabilities are established for uncertain tax positions expected to be taken in income tax returns when such positions are judged to meet the “more-likely-than-not” threshold based on the technical merits of the positions. Estimated interest and penalties related to uncertain tax positions are included as a component of other expenses. Through December 31, 2020, the Company has not identified any uncertain tax positions that it has taken. U.S. income tax returns for the years ended December 31, 2017 through December 31, 2020 and the Chinese income tax return for the year ended December 31, 2020 are open for possible examination. Under the current tax law in the PRC, the Company is and will be subject to the enterprise income tax rate of 25%. There was no provision for income taxes for the three and six months ended June 30, 2021 and 2020, respectively due to continued net losses of the Company. As of June 30, 2021, the Company had net operating loss carryforwards for PRC tax purposes of approximately $39.8 million which are available to offset any future taxable income through 2026. Approximately $20.2 million of these carryforwards will expire in December 2021. The Company also has net operating losses for United States federal income tax purposes of approximately $7.0 million of which $5.1 million are available to offset future taxable income, if any, through 2039, and $1.9 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year. U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act (the “U.S. Tax Reform”), was signed into law on December 22, 2017. The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, management believes it is not likely for the Company to realize all benefits of the deferred tax assets as of June 30, 2021 and December 31, 2020. Therefore, the Company provided for a valuation allowance against its deferred tax assets of $28,315,151 and $27,666,557 as of June 30, 2021 and December 31, 2020, respectively. The Company also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 11 – FAIR VALUE MEASUREMENTS Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities; Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data; and Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. The Company uses fair value to measure the value of the banker’s acceptance notes it holds at June 30, 2021 and December 31, 2020. The banker’s acceptance notes are recorded at cost which approximates fair value. The Company held the following assets and liabilities recorded at fair value: Fair Value Measurements at June 30, Reporting Date Using Description 2021 Level 1 Level 2 Level 3 Banker’s acceptance notes $ - $ - $ - $ - Total $ - $ - $ - $ - Fair Value Measurements at December 31, Reporting Date Using Description 2020 Level 1 Level 2 Level 3 Banker’s acceptance notes $ 53,736 $ - $ 53,736 $ - Total $ 53,736 $ - $ 53,736 $ -

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	NOTE 12 - STOCKHOLDERS’ EQUITY The Company is authorized to issue 95,000,000 shares of common stock, $0.001 par value, and 5,000,000 shares of preferred stock, $0.001 par value. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company’s Board. According to relevant PRC laws, companies registered in the PRC, including the Company’s PRC subsidiary, Helpson, are required to allocate at least 10% of their after tax income, as determined under the accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach 50% of the company’s registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. The amount designated for general and statutory capital reserves is $8,145,000 at June 30, 2021 and December 31, 2020. 2010 Incentive Plan On November 12, 2010, the Company’s Board adopted the Company’s 2010 Incentive Plan (the “Plan”), which was then approved by stockholders on December 22, 2010. On October 17, 2019, the Board of Directors approved the First Amendment to the 2010 Incentive Plan (the “Amendment”), pursuant to which the term of the 2010 Incentive Plan was extended to December 31, 2029. The Amendment was adopted by the shareholders on December 19, 2019. The Plan gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through June 30, 2021, there were 2,175,000 shares of restricted stock granted and outstanding under the Plan. No options were outstanding as of June 30, 2021 under the Plan. The Company recognized no compensation expense related to the awards of common shares and the grants and modifications of stock options during each of the six months ended June 30, 2021 and 2020. There were no securities issued from the Plan during each of the six months ended June 30, 2021 and 2020. As of June 30, 2021, there was no remaining unrecognized compensation expense related to stock options or restricted stock grants.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
REVENUE	NOTE 13 – REVENUE The following table summarizes the Company’s revenues disaggregated by revenue source and geography based on the Company’s PRC based business locations: For the Three Months Ended For the Six Months Ended June 30, June 30, 2021 2020 2021 2020 Domestic Pharmaceuticals $ 2,415,559 $ 2,069,615 $ 4,773,930 $ 3,833,570 Export Medical Test Kits - 1,701,108 - 1,701,108 $ 2,415,559 $ 3,770,723 $ 4,773,930 $ 5,534,678 There were no sales of medical test kits within the PRC.

Risks & Uncertainties

Risks & Uncertainties	6 Months Ended
	Jun. 30, 2021
Risks and Uncertainties [Abstract]
RISKS & UNCERTAINTIES	NOTE 14 – RISKS & UNCERTAINTIES Current vulnerability due to certain concentrations For the six months ended June 30, 2021, no customer accounted for more than 10% of sales and three customers accounted for 52.3%, 11.3% and 10.3% of accounts receivable. Two suppliers accounted for 37.8% and 13.9% of raw material purchases, and three different products accounted for 30.1%, 20.2% and 12.7% of revenue. For the six months ended June 30, 2020, one customer accounted for 30.7% of sales and two customers respectively accounted for 49.8% and 10.7% of accounts receivable. Two suppliers respectively accounted for 39.0% and 18.6% of raw material purchases, and three different products respectively accounted for 30.8%, 21.4% and 13.9% of revenue. Nature of Operations Impact from the New Coronavirus Global Pandemic (“COVID-19”) Economic environment - In addition, all of the Company’s revenue is denominated in the PRC’s currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Organization and Nature of Operations	Organization and Nature of Operations – Onny acquired 100% of the ownership in Helpson on May 25, 2005, by entering into an Equity Transfer Agreement with Helpson’s three former shareholders. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishment of Enterprises with Foreign Investment in the PRC on the same day. Helpson received its business license evidencing its Wholly Foreign Owned Enterprise (“WFOE”) status on June 21, 2005. Helpson is principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the PRC. All of its operations are conducted in the PRC, where its manufacturing facilities are located. Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The majority of its pharmaceutical products are sold on a prescription basis and all have been approved for at least one or more therapeutic indications by the National Medical Products Administration (the “NMPA”, formerly China Food and Drug Administration, or CFDA) based upon demonstrated safety and efficacy.
Liquidity and Going Concern	Liquidity and Going Concern As of June 30, 2021, the Company had cash and cash equivalents of $1.8 million and an accumulated deficit of $30.4 million. The Company’s Chairperson, Chief Executive Officer and Interim Chief Financial Officer has advanced an aggregate of $1,469,452 at June 30, 2021 to provide working capital and enable the Company to make the required payments related to its construction loan facility. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to the production of its existing products, debt service costs and costs of selling and administrative costs. These conditions raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued. To alleviate the conditions that raise substantial doubt about the Company’s ability to continue as a going concern, management plans to enhance the sales model of advance payment, and further strengthen its collection of accounts receivable. Further, the Company is currently exploring strategic alternatives to accelerate the launch of nutrition products. In addition, management believes that the Company’s existing fixed assets can serve as collateral to support additional bank loans. While the current plans will allow the Company to fund its operations in the next twelve months, there can be no assurance that the Company will be able to achieve its future strategic alternatives raising substantial doubt about its ability to continue as a going concern. Pursuant to the requirements of Accounting Standards Codification (ASC) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern Under ASC 205-40, the strategic alternatives being pursued by the Company cannot be considered probable at this time because none of the Company’s current plans have been finalized at the time of the issuance of these financial statements and the implementation of any such plan is not probable of being effectively implemented as none of the plans are entirely within the Company’s control. Accordingly, substantial doubt is deemed to exist about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued. The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.
Consolidation and Basis of Presentation	Consolidation and Basis of Presentation Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is party to the transaction are included in the results of operations. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments of a normal recurring nature that are necessary for a fair presentation of the results for the interim periods presented. All significant intercompany transactions and balances are eliminated on consolidation. However, the results of operations included in such financial statements may not necessary be indicative of annual results. Such financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 filed with the Securities and Exchange Commission (the “SEC”) on March 26, 2021 (“2020 Annual Report”).
Accounting Estimates	Accounting Estimates The Company uses the same accounting policies in preparing its quarterly and annual financial statements. Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted.
Reclassification	Reclassification
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments – Credit Losses (Topic 326) In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes”. From time to time, the FASB or other standards setting bodies issue new accounting pronouncements. Updates to the FASB ASC are communicated through issuance of ASUs. Unless otherwise discussed, the Company believes that the recently issued guidance, whether adopted or to be adopted in the future, is not expected to have a material impact on its consolidated financial statements upon adoption.

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of inventory	June 30, December 31, 2021 2020 Raw materials $ 1,755,110 $ 2,081,745 Work in process 461,293 662,999 Finished goods 761,657 960,375 Total Inventory $ 2,978,060 $ 3,705,119

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets	June 30, December 31, 2021 2020 Permit of land use $ 436,011 $ 431,681 Building 10,124,855 10,024,303 Plant, machinery and equipment 29,306,831 29,018,708 Motor vehicle 332,967 329,660 Office equipment 274,687 259,175 Total 40,475,351 40,063,527 Less: accumulated depreciation (26,129,229 ) (24,499,327 ) Property, plant and equipment, net $ 14,346,122 $ 15,564,200
Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets	Asset Life - years Permit of land use 40 - 70 Building 20 - 49 Plant, machinery and equipment 5 - 10 Motor vehicle 5 - 10 Office equipment 3-5

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	June 30, December 31, 2021 2020 Gross carrying amount $ 5,225,716 $ 5,173,818 Accumulated amortization (5,060,774 ) (4,991,672 ) Net carrying amount $ 164,942 $ 182,146

Other Payables (Tables)

Other Payables (Tables)	6 Months Ended
	Jun. 30, 2021
Other Payables [Abstract]
Schedule Other Payables	June 30, December 31, 2021 2020 Compensation payable to officer $ 1,820,528 $ 1,815,990 Compensation and interest to related party 397,259 382,486 Other payables expenses $ 833,907 $ 549,732 Total Other Payables $ 3,051,694 $ 2,748,208

Construction Loan Facility an_2

Construction Loan Facility and Lines of Credit (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of principal payments	Year Lines of Construction Total 2021 $ 2,523,181 $ 2,167,149 $ 4,690,330 2022 325,072 - 325,072 $ 2,848,253 $ 2,167,149 $ 5,015,402

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Disclosure Text Block [Abstract]
Schedule of minimum lease payments for the company's operating leases liabilities	2022 $ 89,937 2023 88,420 Total undiscounted cash flows 178,357 Less: Imputed interest (8,464 ) 169,893 Less: Operating lease liabilities, current portion (83,707 ) Operating lease liabilities, net of current portion $ 86,186

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of assets and liabilities recorded at fair value	Fair Value Measurements at June 30, Reporting Date Using Description 2021 Level 1 Level 2 Level 3 Banker’s acceptance notes $ - $ - $ - $ - Total $ - $ - $ - $ - Fair Value Measurements at December 31, Reporting Date Using Description 2020 Level 1 Level 2 Level 3 Banker’s acceptance notes $ 53,736 $ - $ 53,736 $ - Total $ 53,736 $ - $ 53,736 $ -

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
Ssdule of revenues	For the Three Months Ended For the Six Months Ended June 30, June 30, 2021 2020 2021 2020 Domestic Pharmaceuticals $ 2,415,559 $ 2,069,615 $ 4,773,930 $ 3,833,570 Export Medical Test Kits - 1,701,108 - 1,701,108 $ 2,415,559 $ 3,770,723 $ 4,773,930 $ 5,534,678

Organization and Significant _2

Organization and Significant Accounting Policies (Details) - USD ($)	Jun. 30, 2021	May 25, 2005
Organization and Significant Accounting Policies (Details) [Line Items]
Cash and cash equivalents	$ 1,800,000
Accumulated deficit	30,400,000
Management [Member]
Organization and Significant Accounting Policies (Details) [Line Items]
Working capital	$ 1,469,452
Subsidiaries [Member]
Organization and Significant Accounting Policies (Details) [Line Items]
Equity method investment, ownership percentage	100.00%
Subsidiaries One [Member]
Organization and Significant Accounting Policies (Details) [Line Items]
Equity method investment, ownership percentage	100.00%
Subsidiaries Three [Member]
Organization and Significant Accounting Policies (Details) [Line Items]
Equity method investment, ownership percentage		100.00%

Inventory (Details) - Schedule

Inventory (Details) - Schedule of inventory - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Schedule of inventory [Abstract]
Raw materials	$ 1,755,110	$ 2,081,745
Work in process	461,293	662,999
Finished goods	761,657	960,375
Total Inventory	$ 2,978,060	$ 3,705,119

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expanse	$ 690,943	$ 640,473	$ 1,381,650	$ 1,287,586

Property, Plant and Equipment_3

Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Abstract]
Permit of land use	$ 436,011	$ 431,681
Building	10,124,855	10,024,303
Plant, machinery and equipment	29,306,831	29,018,708
Motor vehicle	332,967	329,660
Office equipment	274,687	259,175
Total	40,475,351	40,063,527
Less: accumulated depreciation	(26,129,229)	(24,499,327)
Property, plant and equipment, net	$ 14,346,122	$ 15,564,200

Property, Plant and Equipment_4

Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets	6 Months Ended
	Jun. 30, 2021
Minimum [Member] | Permit Of Land Use [Member]
Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Line Items]
Estimated useful lives	40 years
Minimum [Member] | Building [Member]
Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Line Items]
Estimated useful lives	20 years
Minimum [Member] | Plant, Machinery and Equipment [Member]
Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Motor Vehicle [Member]
Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Line Items]
Estimated useful lives	5 years
Minimum [Member] | Office Equipment [Member]
Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Line Items]
Estimated useful lives	3 years
Maximum [Member] | Permit Of Land Use [Member]
Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Line Items]
Estimated useful lives	70 years
Maximum [Member] | Building [Member]
Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Line Items]
Estimated useful lives	49 years
Maximum [Member] | Plant, Machinery and Equipment [Member]
Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Line Items]
Estimated useful lives	10 years
Maximum [Member] | Motor Vehicle [Member]
Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Line Items]
Estimated useful lives	10 years
Maximum [Member] | Office Equipment [Member]
Property, Plant and Equipment (Details) - Schedule of depreciation is computed on straight-line basis over estimated useful lives of assets [Line Items]
Estimated useful lives	5 years

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible assets useful life , description			Approved medical formulas are amortized from the date NMPA approval is obtained over their individually identifiable estimated useful life, which range from ten to thirteen years.
Amortization expense relating to intangible assets	$ 9,517	$ 8,676	$ 18,997	$ 17,484

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of intangible assets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Schedule of intangible assets [Abstract]
Gross carrying amount	$ 5,225,716	$ 5,173,818
Accumulated amortization	(5,060,774)	(4,991,672)
Net carrying amount	$ 164,942	$ 182,146

Other Payables (Details) - Sche

Other Payables (Details) - Schedule Other Payables - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Schedule Other Payables [Abstract]
Compensation payable to officer	$ 1,820,528	$ 1,815,990
Compensation and interest to related party	397,259	382,486
Other payables expenses	833,907	549,732
Total Other Payables	$ 3,051,694	$ 2,748,208

Related Party Transactions (Det

Related Party Transactions (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Jul. 08, 2019USD ($)	Jul. 08, 2019CNY (¥)
Related Party Transactions (Details) [Line Items]
Advance received	$ 1,354,567		$ 1,354,567			$ 1,354,567
Interest rate	1.00%		1.00%
Interest expense	$ 3,386	$ 3,386	$ 6,773	$ 6,773
Other payables		397,259		397,259		382,486
Borrowings from related parties	1,469,452		1,469,452			779,861
Other payables					$ 1,820,528	$ 1,815,990
Chief Executive Officer [Member]
Related Party Transactions (Details) [Line Items]
Advance received	917,827		917,827
Chief Financial Officer [Member]
Related Party Transactions (Details) [Line Items]
Repaid advance	251,861		251,861
Management [Member]
Related Party Transactions (Details) [Line Items]
Interest rate							4.35%	4.35%
Interest expense	$ 7,539	$ 7,433	$ 15,050	$ 14,754
Loan agreement to borrow cash							$ (738,379)	¥ 4,770,000

Banker's Acceptance Notes Pay_2

Banker's Acceptance Notes Payable (Details) - 1 months ended Apr. 30, 2016 $ in Millions	USD ($)	CNY (¥)
Banker's Acceptance Notes Payable (Details) [Line Items]
Maximum amount of agreement | $	$ 4.5
Agreement payments fees, description	In addition, the agreement calls for the payment of fees equal to 0.05% of the note amount to the bank.
RMB [Member]
Banker's Acceptance Notes Payable (Details) [Line Items]
Maximum amount of agreement | ¥		¥ 30,000,000

Construction Loan Facility an_3

Construction Loan Facility and Lines of Credit (Details)	1 Months Ended			3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2020USD ($)	Apr. 30, 2020USD ($)	Jun. 21, 2013USD ($)	Jun. 30, 2021USD ($)	Mar. 31, 2021USD ($)	Jun. 30, 2020USD ($)	Jun. 30, 2021USD ($)	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)	Jul. 10, 2021USD ($)	Jul. 10, 2021CNY (¥)	Jun. 30, 2021CNY (¥)	Jun. 25, 2021	Mar. 31, 2021CNY (¥)	Jul. 31, 2020USD ($)	Jun. 30, 2020CNY (¥)	Apr. 30, 2020CNY (¥)	Jun. 21, 2013CNY (¥)
Construction Loan Facility and Lines of Credit (Details) [Line Items]
Construction loan amount	$ 1,200,000	$ 1,400,000	$ 13,000,000			$ 1,200,000		$ 1,200,000								¥ 8,500,000
Description of loan interest rates	The loan bears interest at the rate of 4.05% per annum.		The loan bears interest based upon 110% of the PRC government’s eight-year term rate effective on the actual draw-down date, subject to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates.  The interest rate has remained at 5.39% on each of the July 10 anniversary dates since inception.  The loan required interest only payments for the first two years. Beginning July 11, 2015, the principal was due in at least two (2) annual installments with the first annual payment being due within six month period after July 10, 2015 and the second annual payment being due July 10, 2016 and each following year over the next five years through July 11, 2021 on the identical terms as described above for 2015.				The loan bears interest at a rate of 4.25% per annum.
Principal Payments		$ 400,000		$ 154,516			$ 154,516					¥ 1,000,000			$ 700,000		¥ 5,000,000
Laon facility term		Advances on the line of credit are due two years from the date of the advance.
Line of credit, description					Total interest expense under this facility for the three months ended June 30, 2021 and 2020 was $11,550 and $4,963, respectively.
Total interest expense				$ 72,392		63,144	$ 143,657	125,147
Interest rate				1.00%			1.00%					1.00%
Third party guarantee [Member]
Construction Loan Facility and Lines of Credit (Details) [Line Items]
Principal Payments				$ 120,000	$ 300,000		$ 120,000			$ 2,200,000	¥ 14,000,000	¥ 800,000		¥ 2,000,000
Total interest expense							23,517	4,963
Bank of Communications [Member]
Construction Loan Facility and Lines of Credit (Details) [Line Items]
Total interest expense				11,550		$ 0	23,517	0
Interest rate													4.17%
China CITIC Bank [Member]
Construction Loan Facility and Lines of Credit (Details) [Line Items]
Line of credit, description									The Company obtained a line of credit of RMB 3,200,000 (approximately $0.5 million) from China CITIC Bank in September 2020 and obtained an advance of RMB 2,343,340 (approximately $0.3 million), and the remaining of RMB 856,660 (approximately $0.1 million) in October 2020 under this line. The loan bears interest at the rate of 4.50% per annum. The line of credit is due in one year on the anniversary date of the advance
Total interest expense				$ 5,697			$ 11,249	$ 0
RMB [Member]
Construction Loan Facility and Lines of Credit (Details) [Line Items]
Construction loan amount | ¥																	10,000,000	¥ 80,000,000
Principal Payments | ¥																	¥ 3,000,000
RMB [Member] | China CITIC Bank [Member]
Construction Loan Facility and Lines of Credit (Details) [Line Items]
Total interest expense									$ 0

Construction Loan Facility an_4

Construction Loan Facility and Lines of Credit (Details) - Schedule of principal payments	Jun. 30, 2021USD ($)
Debt Instrument [Line Items]
2021	$ 4,690,330
2022	325,072
Total	5,015,402
Lines of Credit [Member]
Debt Instrument [Line Items]
2021	2,523,181
2022	325,072
Total	2,848,253
Construction Loan Facility [Member]
Debt Instrument [Line Items]
2021	2,167,149
2022
Total	$ 2,167,149

Leases (Details)

Leases (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Leases (Textual)
Operating leases cost	$ 24,793	$ 22,265	$ 48,760	$ 44,494
Cash flows from operating leases	26,352	$ 23,665	51,827	$ 49,376
Operating lease right of use assets	169,807		169,807		$ 49,687
Operating leases liabilities	$ 169,893		$ 169,893		$ 52,070
Weighted average remaining lease term	1 year 11 months 23 days		1 year 11 months 23 days
Weighted average discount rate	4.75%		4.75%

Leases (Details) - Schedule of

Leases (Details) - Schedule of minimum lease payments for the company's operating leases liabilities - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Schedule of minimum lease payments for the company's operating leases liabilities [Abstract]
2022	$ 89,937
2023	88,420
Total undiscounted cash flows	178,357
Less: Imputed interest	(8,464)
Total	169,893
Less: Operating lease liabilities, current portion	(83,707)	$ (52,070)
Operating lease liabilities, net of current portion	$ 86,186

Income Taxes (Details)

Income Taxes (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Enterprise income tax rate	25.00%
Net operating loss carryforwards for PRC tax	$ 39,800,000
Net operating loss expiration, description	Approximately $20.2 million of these carryforwards will expire in December 2021. The Company also has net operating losses for United States federal income tax purposes of approximately $7.0 million of which $5.1 million are available to offset future taxable income, if any, through 2039, and $1.9 million are available for carryforward indefinitely subject to a limitation of 80% of taxable income for each tax year.
Description of federal corporate income tax rate	The U.S. Tax Reform significantly modified the U.S. Internal Revenue Code by, among other things, reducing the statutory U.S. federal corporate income tax rate from 35% to 21% for taxable years beginning after December 31, 2017; limiting and/or eliminating many business deductions; migrating the U.S. to a territorial tax system with a one-time transition tax on a mandatory deemed repatriation of previously deferred foreign earnings of certain foreign subsidiaries; subject to certain limitations, generally eliminating U.S. corporate income tax on dividends from foreign subsidiaries; and providing for new taxes on certain foreign earnings.
Valuation allowance for deferred tax assets	$ 28,315,151	$ 27,666,557

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker's acceptance notes		$ 53,736
Total		53,736
Level 1 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker's acceptance notes
Total
Level 2 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker's acceptance notes		53,736
Total		53,736
Level 3 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities recorded at fair value [Line Items]
Banker's acceptance notes
Total

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized	95,000,000	95,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
After-tax net income, percentage	10.00%
Reserve account balances, percentage	50.00%
General and statutory capital reserves amount (in Dollars)	$ 8,145,000	$ 8,145,000
2010 Incentive Plan [Member]
Stockholders' Equity (Details) [Line Items]
Common stock issued	4,000,000
Restricted stock granted and outstanding	2,175,000

Revenue (Details) - Schedule of

Revenue (Details) - Schedule of revenues - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Capitalized Costs of Unproved Properties Excluded from Amortization [Line Items]
Revenue	$ 2,415,559	$ 3,770,723	$ 4,773,930	$ 5,534,678
Domestic Pharmaceuticals [Member]
Capitalized Costs of Unproved Properties Excluded from Amortization [Line Items]
Revenue	$ 2,415,559	2,069,615	$ 4,773,930	3,833,570
Export Medical Test Kits [Member]
Capitalized Costs of Unproved Properties Excluded from Amortization [Line Items]
Revenue		$ 1,701,108		$ 1,701,108

Risks & Uncertainties (Details)

Risks & Uncertainties (Details)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Sales Revenue, Net [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	10.00%	30.70%
Number of customers	3	1
Accounts Receivable [Member]
Risks & Uncertainties (Details) [Line Items]
Number of customers		2
Raw Material Purchases [Member]
Risks & Uncertainties (Details) [Line Items]
Number of suppliers	2	2
Raw Material Purchases [Member] | Suppliers [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	37.80%	39.00%
Raw Material Purchases [Member] | Supplier Two [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	13.90%	18.60%
Revenue one [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	30.10%	30.80%
Revenue two [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	20.20%	21.40%
Revenue three [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	12.70%	13.90%
Customer One [Member] | Accounts Receivable [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	52.30%	49.80%
Customer Two [Member] | Accounts Receivable [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	11.30%
Customer Two [Member] | Accounts Receivable [Member]
Risks & Uncertainties (Details) [Line Items]
Concentrations risk, percentage	10.30%	10.70%